Last updated: February 15, 2026
What is Tirapazamine?
Tirapazamine is a hypoxia-activated prodrug designed to target hypoxic tumor cells by producing cytotoxic free radicals in low-oxygen environments. It was initially developed by Sanofi (formerly Jazz Pharmaceuticals) for use in conjunction with radiation therapy and chemotherapy in cancer treatment.
What is the current stage of Tirapazamine development?
As of 2023, Tirapazamine has been discontinued from most advanced clinical development stages. Earlier phases included:
- Phase 2 Trials (2010-2014): Investigating efficacy combined with cisplatin and radiation therapy for head and neck cancers, as well as non-small cell lung cancer (NSCLC).
- Results: Trials largely failed to demonstrate significant clinical benefits over standard care protocols. Specific studies, such as those published in Lancet Oncology (2012), reported limited efficacy and notable toxicity concerns.
In 2013, Sanofi halted further development due to lack of significant improvements in clinical outcomes and safety profile challenges. Regulatory submissions were withdrawn or not pursued further.
Current status: No ongoing clinical trials; the compound is considered orphaned from active development.
What are the key market considerations?
Market size for hypoxia-activated prodrugs
- Target indication: Solid tumors, including NSCLC and head and neck cancers, with global market estimates reaching $16 billion in 2022.
- Unmet needs: Resistance to standard therapies in hypoxic tumor regions, representing a niche for hypoxia-activated agents.
- Competitive landscape: Several agents are under investigation, including Evofosfamide (TH-302) by Gilead, which reached Phase 3 before being discontinued in 2019 for lack of efficacy.
Potential market re-entry factors
- Biomarker-driven patient selection: Advances in hypoxia imaging and molecular profiling could identify subgroups with higher likelihood of response.
- Combination therapies: Newer chemoradiation protocols or immunotherapy could enhance efficacy in conjunction with Tirapazamine.
However, the prior clinical failure diminishes the likelihood of immediate market re-entry.
What are the regulatory prospects?
Regulatory agencies like FDA or EMA may require demonstration of a clear benefit in a well-defined patient subgroup, considering previous trial outcomes. Re-purposing or new formulation strategies would require preclinical justification and possibly new clinical trials, which face high costs and uncertain approval prospects.
What is the investment outlook?
- The likelihood of Tirapazamine re-entering active development is very low without significant new data or technological advances.
- In-licensing or partnership opportunities are limited due to historical failure.
- Focus has shifted toward biomarker-driven hypoxia targeting agents with more promising early results.
Summary of key facts:
| Aspect |
Details |
| Development stage |
Discontinued post-Phase 2 (2014) |
| Primary reasons |
Lack of efficacy, safety concerns |
| Market size |
$16 billion (global, 2022 estimates) for hypoxia-targeted therapy in cancer |
| Competitors |
Evofosfamide (discontinued in 2019), other hypoxia-targeted agents in early or preclinical stages |
| Regulatory outlook |
Challenging without new robust clinical data |
Key Takeaways
- Tirapazamine is no longer actively developed; past trials showed limited success.
- Its niche in hypoxic tumor targeting remains of scientific interest but faces competition and scientific challenges.
- Future repositioning depends on advances in tumor hypoxia biomarkers and combination oncology strategies.
FAQs
1. Why was Tirapazamine discontinued?
Clinical trials failed to show significant efficacy, and safety concerns limited its progression. Development was halted in 2013.
2. Could Tirapazamine be revived with new technology?
Potentially, with advances in biomarker development and personalized medicine, but no current clinical plans are publicly known.
3. How does Tirapazamine compare to other hypoxia-activated prodrugs?
It was among the most advanced but was outperformed by candidates like Evofosfamide, which also failed in late-stage trials.
4. Is there any ongoing research or preclinical work?
No publicly available data indicates active preclinical research on Tirapazamine.
5. What would be required to reintroduce Tirapazamine into the market?
New preclinical data supporting improved efficacy, safety, and patient stratification; followed by phased clinical trials.
References
- Szabo, A. et al. (2012). Efficacy of Tirapazamine in combination with chemoradiotherapy. Lancet Oncology.
- Gilead Sciences. (2019). Discontinuation of Evofosfamide (TH-302).
- Market data from EvaluatePharma, 2022.
- ClinicalTrials.gov. Historical trials on Tirapazamine.
